New Rhein Healthcare Investors

Pennsylvania
New Rhein is a venture capital firm focused on healthcare therapeutics and medical devices. Its partners and associates are former industry executives with operational and transactional experience. New Rhein invests in businesses that utilize proven products in new applications (e.g., new indications, new dosage forms, 505(b2)). The companycompiles syndicates of operationally focused investors who together bring a wealth of experience and a broad network of relationships to support its portfolio companies in the development, regulatory, reimbursement, marketing, and/or contract manufacturing. New Rhein provides an understanding of what would be attractive to strategic partners and works backward to help its portfolio companies build their value proposition. Prior New Rhein investments have included ophthalmic pharmaceuticals, molecular diagnostics, and respiratory drug/device inhalers.
Founded:2011
Firm Location:Pennsylvania • New York, New York • Philadelphia, Pennsylvania • Brussels
Investor Firms That Co-Invest with New Rhein Healthcare Investors
New Rhein Healthcare Investors Team
Photo of Amy Bevacqua, Vice President at New Rhein Healthcare Investors
Amy Bevacqua
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY)
Photo of Ivan Gergel, Managing Partner at New Rhein Healthcare Investors
Ivan Gergel
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Pennsylvania
Photo of Greg Parekh, Managing Partner at New Rhein Healthcare Investors
Greg Parekh
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Brussels
Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in Data Services (Series A), Investors in BioTech (Series A), Investors in AI (Series A)
Photo of Nishant Rastogi, Vice President at New Rhein Healthcare Investors
Nishant Rastogi
Sweet spot: $1.5M
Range: $1M - $5.0M
Investors in Philadelphia (PA)
Investors in Diagnostics (Series B), Investors in Impact (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Pharmaceuticals (Series B), Investors in Medical Devices (Series B), Investors in Impact (Series A), Investors in Impact (Seed), Investors in Medical Devices (Series A), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in Diagnostics (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Impact (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in BioTech (Series A), Investors in Medical Devices (Series B), Investors in BioTech (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Pharmaceuticals (Series B), Investors in Impact (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series A), Investors in Medical Devices (Series A), Investors in Digital Health (Series B), Investors in Impact (Seed), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in Health & Hospital Services (Seed), Investors in New York City (Other Lists)
Photo of Jonathan Soll, Analyst at New Rhein Healthcare Investors
Jonathan Soll
Sweet spot: $25.0M
Range: $20.0M - $50.0M
Investors in Philadelphia (PA)
Investors in Drug Delivery (Series A), Investors in Drug Delivery (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Drug Delivery (Series A), Investors in Drug Delivery (Seed), Investors in Medical Devices (Series A), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in Therapeutics (Series A), Investors in Consumer Health (Series A), Investors in Diagnostics (Series A), Investors in Consumer Health (Seed), Investors in BioTech (Series A), Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Medical Devices (Series A), Investors in Diverse Investors (Other Lists), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Seed), Investors in Consumer Health (Series A), Investors in Consumer Health (Seed), Investors in New York City (Other Lists), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in BioTech (Seed), Investors in Digital Health (Seed)